Does cafeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury?

Phase 4

Conditions: heart infarction
Ischemia-reperfusion injury
10003216

Registration Number: NL-OMON30751

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 24

Inclusion Criteria

Male
age between 18-50 yrs
signed informed consent

Exclusion Criteria

-Cardiovascular disease
-Hypertension (systole > 140 mmHg, diastole > 90 mmHg)
-Hypercholesterolemia (fasting total cholesterol > 6,0 mmol/l)
-Drug abuse
-Concomittant medication use
-Inability to perform the ischemic isometric muscle contraction
-Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
-Alanine-Amino-Transferase (ALAT) >90U/L (more than twice the upper level of the normal
range)
-Creatinine Kinase (CK) >340U/L (more than twice the upper level of the normal range)
-Participation in any trial concerning medicinal products
during the last 60 days prior to this study.
-Participation in clinical trial involving administration of radioactivity more than 5mSv, during the 5 years prior to this study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Annexin A5 targeting (% difference in radioactivity (counts per pixel) between<br /><br>experimental and control thenar muscle after ischemic exercise, as a indicator<br /><br>for ischemia reperfusion injury. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-Workload (product of 50% of the maximum forearm force and duration of the<br /><br>ischemic exercise)<br /><br>-The effect of one-week treatment of rosuvastatine 20mg once daily on lipid<br /><br>spectrum.<br /><br>-The caffeine serum concentration after 24 hour abstinence, and after infusion<br /><br>of cafeine (4mg/kg) or placebo.</p><br>